Randomized, Open Label, Non-inferiority Study of Micafungin Versus Standard Care for the Prevention of Invasive Fungal Disease in High Risk Liver Transplant Recipients

Next Previous
Trial Profile

Randomized, Open Label, Non-inferiority Study of Micafungin Versus Standard Care for the Prevention of Invasive Fungal Disease in High Risk Liver Transplant Recipients

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Micafungin (Primary)
  • Indications Mycoses
  • Focus Therapeutic Use
  • Acronyms TENPIN
  • Sponsors Astellas Pharma; Astellas Pharma Europe Ltd

    • Most Recent Events

    • 18 Oct 2013 New trial record
    • 11 Sep 2013 Primary endpoint 'Infection-rate' has been met.
    • 11 Sep 2013 Results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top